Johnson & Johnson Ended ExPEC9V Vaccine Trial
The company halted development of the experimental E. coli vaccine after a Phase 3 study showed no significant protective effect.
Updated on Oct. 14, 2026 in COVID-19
Live Poll
Does a high-profile vaccine trial failure make you less likely to participate in future medical research?
Johnson & Johnson has discontinued development of its ExPEC9V vaccine after the Phase 3 E.mbrace trial failed to show a meaningful protective effect against invasive E. coli disease. The study was ended early because the vaccine did not meet its primary efficacy goals.
Why it matters
The trial was terminated due to a lack of efficacy and a lower-than-anticipated incidence of invasive disease among participants. Researchers determined the vaccine did not provide the intended protection against serious infections for the elderly population.
The E.mbrace trial included over 17,000 participants with a median age of 70 years, of which 70.6% were women. Local adverse events were reported in 35% of the vaccine group compared to 9% in the placebo group.
The players
Johnson & Johnson
A multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
The details
Participants received a single intramuscular injection of the vaccine or a placebo, with the study focused on individuals aged 60 and older who possessed at least one invasive E. coli risk factor. While antibody titers increased within 30 days of vaccination, the clinical outcome failed to demonstrate a reduction in invasive disease cases.
Timeline
Prior 2 years: History of urinary tract infection required for enrollment.
30 days: Antibody titers rose in the vaccine group post-vaccination.
At least 29 days post-vaccination: Primary endpoint eligibility window.
366 days: Antibody levels declined but remained higher than placebo.
Health Landscape
The termination of the E.mbrace Phase 3 trial highlights the persistent challenges in developing effective prophylactic vaccines for common bacterial infections in aging populations. This failure marks a significant departure from expectations for preventative treatments for invasive E. coli in older adults.
Patients who were enrolled in the study should consult with their healthcare providers regarding the trial's conclusion and any potential follow-up care. The discontinuation of the vaccine means it will not be an available preventative option for managing E. coli infection risks in the elderly.
The takeaway
The failure of this vaccine trial underscores the complexity of targeting bacterial pathogens with preventive shots in older adults. Future preventative health strategies for this demographic may need to pivot toward alternative methods for reducing infection risk.
Further reading
For more information on current developments in vaccine research, visit the COVID-19 section.
Live Poll
Does a high-profile vaccine trial failure make you less likely to participate in future medical research?
